Proactive Investors Australia | Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in Portugal for ... MarketWatch (press release) ILUVIEN is Alimera's sustained release intravitreal implant that delivers sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic DME. The clinical trial data showed that in patie nts with chronic DME at ... PSivida Says Portugal Grants ILUVIEN Marketing Authorization To Treat ChronicDME |
Tuesday, June 5, 2012
Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in Portugal for ... - MarketWatch (press release)
humojo.wordpress.com
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment